Key result
Ambulatory COVID-19 in pregnancy is not associated with increased major cardiovascular complications.
Why the study?
Data regarding cardiovascular outcomes among pregnant women with COVID-19, particularly in community-based ambulatory populations, remain limited as most studies focused on hospitalized or critically ill patients.
Does COVID-19 infection during pregnancy increase the risk of cardiovascular complications in pregnant women managed in ambulatory settings?
Cohort (n=8,136)
Does COVID-19 infection during pregnancy increase the risk of cardiovascular complications in pregnant women managed in ambulatory settings?
Odds Ratio: 1 (95% CI 0.27–3.74)
Absolute Event Rate: 0.15% vs 0.15%
p-value: p=1.000
COVID-19 infection during pregnancy in ambulatory community settings is not associated with an increased risk of major maternal cardiovascular complications.
No elevated major CV risk in ambulatory pregnant women with COVID-19; extends inpatient data but leaves confirmation to prospective studies.
Background SARS-CoV-2 has been linked to cardiovascular complications in the general population. However, data regarding cardiovascular outcomes among pregnant women remain limited, particularly in community-based ambulatory populations, as most previous studies focused primarily on hospitalized or critically ill patients. In this retrospective population-based matched cohort study, we evaluated whether COVID-19 infection during pregnancy is associated with an increased incidence of cardiovascular complications among pregnant women managed predominantly in outpatient settings. Methods We conducted a retrospective population-based matched cohort study using electronic health record data from pregnant women between 2020 and 2025. Women with COVID-19 during pregnancy were matched 1:1 to women without documented COVID-19 during pregnancy according to demographic, obstetric, and clinical characteristics. The final analytical cohort included 4,068 women in each group. Cardiovascular outcomes during pregnancy and within a year since last menstrual period were assessed. Baseline demographic and obstetric characteristics were comparable between the COVID-19 and control groups. No significant differences were observed between the groups in the incidence of major cardiovascular complications, either when analyzed individually or as a composite endpoint (0.15% vs. 0.15%; OR 1.00, 95% CI 0.27–3.74). Specifically, there were no significant differences in the occurrence of atrial fibrillation/flutter, congestive heart failure, cardiomyopathy, myocarditis, pulmonary embolism, or deep venous thrombosis. In contrast, cough and backache were significantly more frequent among women with COVID-19 than among matched controls (6.88% vs. 4.87%; OR 1.45, 95% CI 1.19–1.75; 13.8% vs. 11.8%; OR 1.20, 95% CI 1.05–1.37; p = 0.007 respectively). Conclusions Our findings suggest that among pregnant women in ambulatory community settings, COVID-19 infection is not associated with an increased risk of major cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Davarashvili et al. (2026) conducted a cohort in Pregnancy (n=8,136). COVID-19 infection vs. Women without documented COVID-19 during pregnancy was evaluated on Composite of major adverse cardiovascular events (myocarditis, cardiomyopathy, atrial fibrillation or flutter, congestive heart failure, myocardial infarction, pulmonary embolism, or deep venous thrombosis) (OR 1.00, 95% CI 0.27-3.74, p=1.000). COVID-19 infection during pregnancy in ambulatory settings was not associated with an increased risk of major cardiovascular complications compared to matched unexposed controls (OR 1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: